SCHEMBL3517029

SCHEMBL3517029

Nc1cc(F)c2[nH]nc(NC(=O)c3ccccc3)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 2/20 0.48
FGFR2 P21802 1/20 0.48
FGFR3 P22607 1/20 0.48
JAK2 O60674 1/20 0.46
JAK1 P23458 1/20 0.46
HDAC6 Q9UBN7 2/20 0.46
CDK7 P50613 9/20 0.45
HDAC1 Q13547 2/20 0.45
CDK2 P24941 2/20 0.43
MAP4K4 O95819 1/20 0.43
CDK1 P06493 1/20 0.43
CLK2 P49760 1/20 0.43
GSK3B P49841 1/20 0.43
CSNK2A1 P68400 1/20 0.43
CDK5 Q00535 1/20 0.43
MAP4K2 Q12851 1/20 0.43
CAMK2B Q13554 1/20 0.43
CAMK2G Q13555 1/20 0.43
CAMK2D Q13557 1/20 0.43
DYRK1A Q13627 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3515842 0.82 HDAC6 (0.49) FGFR1FGFR2FGFR3HDAC6CDK7
SCHEMBL3514489 0.81 MEN1 (0.47) FGFR1FGFR2FGFR3HDAC6CDK7
SCHEMBL761113 0.78 JAK2 (0.62) FGFR1FGFR2FGFR3JAK2JAK1
SCHEMBL30881831 0.73 TP53 (0.50) HDAC6CDK7CDK2MAP4K4CLK2
SCHEMBL29209741 0.73 TP53 (0.50) HDAC6CDK7CDK2MAP4K4CLK2
SCHEMBL757551 0.72 JAK2 (0.46) JAK2JAK1HDAC6HDAC1CDK2
SCHEMBL627899 0.71 FGFR1 (0.65) FGFR1FGFR2FGFR3JAK2JAK1
SCHEMBL31040239 0.71 FGFR1 (0.65) FGFR1FGFR2FGFR3JAK2JAK1
SCHEMBL18812677 0.69 CDK7 (0.63) FGFR1FGFR2FGFR3JAK2JAK1
SCHEMBL627833 0.69 FGFR1 (0.81) FGFR1FGFR2FGFR3HDAC6CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298377-A1 NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS SANOFI-AVENTIS (FR) 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298377-A1 NOVEL SUBSTITUTED INDAZOLES, THE PREPARATION THEREOF AND USE OF SAME IN THERAPEUTICS WEE1, PRMT1, ABL1 FGFR1 1256/4885FGFR2 1507/4885FGFR3 1219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.